ArticleEmerging infectious diseases2026
Investigation of Donor-Transmitted Strongyloides stercoralis Infections in Solid Organ Transplant Recipients, United States, 2012-2024.
Article in Emerging infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Strongyloides stercoralis is a parasitic nematode endemic in tropical and subtropical regions, including parts of the southeastern United States, that can be transmitted via organ donation. As of October 2025, the Organ Procurement and Transplant Network implemented new policy for screening in deceased US organ donors to reduce the risk for donor-derived Strongyloides infection. To assess the potential effect of policy changes, we reviewed investigations of suspected transplant-related strongyloidiasis in the United States conducted by the Centers for Disease Control and Prevention and partners for solid organ transplants occurring during 2012-2024. During that period, 21 proven donor-derived strongyloidiasis cases originated from 15 unscreened donors. Of donors who were screened, 31 seropositive donors resulted in ivermectin prophylaxis for 77 recipients, none of whom had disease develop. Our findings support the effectiveness of universal organ donor screening and prophylactic ivermectin treatment of recipients to prevent donor-derived Strongyloides infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.